SCYNEXIS, Inc. Stock-Based Compensation
SCYNEXIS, Inc. (SCYX) reported Stock-Based Compensation of $1.15 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-08-10
- SCYNEXIS, Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $568.00K, a 30.73% decline year-over-year.
- SCYNEXIS, Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $580.00K, a 29.18% decline year-over-year.
- SCYNEXIS, Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $687.00K, a 29.97% decline year-over-year.
- SCYNEXIS, Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $526.00K, a 41.62% decline year-over-year.
- SCYNEXIS, Inc. share-based payment arrangement, noncash expense for fiscal 2025 was $2.85M, a 14.76% decline from fiscal 2024.
- SCYNEXIS, Inc. share-based payment arrangement, noncash expense for fiscal 2024 was $3.35M, a 27.52% increase from fiscal 2023.
- SCYNEXIS, Inc. share-based payment arrangement, noncash expense for fiscal 2023 was $2.62M, a 28.81% decline from fiscal 2022.
- SCYNEXIS, Inc. share-based payment arrangement, noncash expense for fiscal 2022 was $3.69M, a 76.53% increase from fiscal 2021.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $568.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $1.15M 10-Q · filed 2026-08-10 | $1.83M derived: sum of 3 quarters · filed 2026-08-10 | $2.36M derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | $580.00K 10-Q · filed 2026-05-11 | $1.27M derived: sum of 2 quarters · filed 2026-05-11 | $1.79M derived: sum of 3 quarters · filed 2026-05-11 | $2.61M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | $687.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04 | $1.21M derived: sum of 2 quarters · filed 2026-03-04 | $2.03M derived: sum of 3 quarters · filed 2026-08-10 | $2.85M 10-K · filed 2026-03-04 |
| 2025-09-30 | $526.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $1.35M derived: sum of 2 quarters · filed 2026-08-10 | $2.17M 10-Q · filed 2025-11-05 | $3.15M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | $820.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $1.64M 10-Q · filed 2026-08-10 | $2.62M derived: sum of 3 quarters · filed 2026-08-10 | $3.52M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | $819.00K 10-Q · filed 2026-05-11 | $1.80M derived: sum of 2 quarters · filed 2026-05-11 | $2.70M derived: sum of 3 quarters · filed 2026-05-11 | $3.46M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | $981.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04 | $1.88M derived: sum of 2 quarters · filed 2026-03-04 | $2.64M derived: sum of 3 quarters · filed 2026-03-04 | $3.35M 10-K · filed 2026-03-04 |
| 2024-09-30 | $901.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $1.66M derived: sum of 2 quarters · filed 2025-11-05 | $2.37M 10-Q · filed 2025-11-05 | $2.92M derived: sum of 4 quarters · filed 2025-11-05 |
| 2024-06-30 | $759.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $1.46M 10-Q · filed 2025-08-13 | $2.02M derived: sum of 3 quarters · filed 2025-08-13 | $2.65M derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | $705.00K 10-Q · filed 2025-05-15 | $1.26M derived: sum of 2 quarters · filed 2025-05-15 | $1.89M derived: sum of 3 quarters · filed 2025-05-15 | $2.62M derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | $557.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-12 | $1.19M derived: sum of 2 quarters · filed 2025-03-12 | $1.92M derived: sum of 3 quarters · filed 2025-03-12 | $2.62M 10-K · filed 2025-03-12 |
| 2023-09-30 | $632.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $1.36M derived: sum of 2 quarters · filed 2024-11-06 | $2.07M 10-Q · filed 2024-11-06 | $2.52M derived: sum of 4 quarters · filed 2024-11-06 |
| 2023-06-30 | $728.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $1.44M 10-Q · filed 2024-08-08 | $1.89M derived: sum of 3 quarters · filed 2024-08-08 | $3.10M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $707.00K 10-Q · filed 2024-05-08 | $1.16M derived: sum of 2 quarters · filed 2024-05-08 | $2.37M derived: sum of 3 quarters · filed 2024-05-08 | $3.47M derived: sum of 4 quarters · filed 2024-05-08 |
| 2022-12-31 | $454.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $1.66M derived: sum of 2 quarters · filed 2024-03-28 | $2.76M derived: sum of 3 quarters · filed 2024-03-28 | $3.69M 10-K · filed 2024-03-28 |
| 2022-09-30 | $1.21M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $2.31M derived: sum of 2 quarters · filed 2023-11-13 | $3.23M 10-Q · filed 2023-11-13 | $3.79M derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | $1.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $2.02M 10-Q · filed 2023-08-14 | $2.58M derived: sum of 3 quarters · filed 2023-08-14 | |
| 2022-03-31 | $922.00K 10-Q · filed 2023-05-10 | $1.48M derived: sum of 2 quarters · filed 2023-05-10 | ||
| 2021-12-31 | $560.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $2.09M 10-K · filed 2023-03-31 | ||
| 2021-09-30 | $1.53M 10-Q · filed 2022-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |